Recently, the United States Food and Drug Administration (FDA) has approved the first AKT inhibitor, capivasertib, in combination with the estrogen receptor antagonist fulvestrant, for the treatment of hormone receptor-positive, HER2-negative breast cancer.29 Here, AKT1 is linked to breast carcinoma.